A new growth hormone with improved convenience in administration will be introduced to Korea’s annual KRW 240 billion growth hormone market with reimbursement in September this year.

The drug is Pfizer's Ngenla Prefilled Pen Inj. Whether Pfizer will use the reimbursement of its new drug as momentum and be able to rise to the top in this market that is being led by domestic companies such as LC Chem and Dong-A ST, is gaining attention.

According to industry sources on the 21st, the Ministry of Health and Welfare announced that it will be newly listing Ngenla Prefilled Pen Inj 24mg and Ngenla Prefilled Pen Inj 60mg with reimbursement from September 1st through the administrative notice